Real World Efficacy, Tolerability and Safety Study of Ubrogepant, Rimegepant, and Lasmiditan

Chia-Chun Chiang, MD

AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW

3 minute

Key messages

  • Real-world data are needed to supplement the efficacy and safety demonstrated in Phase 3 randomized controlled trials of the calcitonin gene-related peptide (CRGP) antagonists ubrogepant, rimegepant, and lasmiditan.
  • Preliminary real-world data collected at a tertiary headache center show ubrogepant provides headache freedom and pain relief at 2 hours for at least one attack in a predominantly chronic migraine patient population.
  • The final results from the present study will provide important clinical evidence that will inform decision­making in clinical practice.

Key messages

  • Real-world data are needed to supplement the efficacy and safety demonstrated in Phase 3 randomized controlled trials of the calcitonin gene-related peptide (CRGP) antagonists ubrogepant, rimegepant, and lasmiditan.
  • Preliminary real-world data collected at a tertiary headache center show ubrogepant provides headache freedom and pain relief at 2 hours for at least one attack in a predominantly chronic migraine patient population.
  • The final results from the present study will provide important clinical evidence that will inform decision­making in clinical practice.

Background

What do we already know about this topic?

  • To date, there are no real-world studies that validate the efficacy and safety of ubrogepant, lasmiditan, and rimegepant in a patient population with complex comorbidities, chronic migraine, multiple ineffective treatment trials, and concurrent usage of other acute and preventive medications.

How was this study conducted?

  • Prospective, real-world study of adult patients with migraine with or without aura (N=100) who were prescribed and had taken at least one dose of ubrogepant, rimegepant and lasmiditan at the Mayo Clinic, Arizona, USA.
  • Each patient underwent a medical chart review and completed a structured questionnaire (15 questions) approximately 1–3 months after treatment was prescribed.

Findings

What does this study add?

  • 32% of patients reported freedom from headache at 2 hours following ubrogepant treatment for one or more attacks.
  • 12% of patients said ubrogepant provided consistent, complete headache freedom at 2 hours.
  • 73% of patients reported pain relief at 2 hours following ubrogepant treatment for one or more attacks.
  • 27% of patients said ubrogepant provided consistent pain relief at 2 hours.
  • The most common adverse events reported were fatigue, nausea, dry mouth, and constipation.
  • Preliminary results for rimegepant and lasmiditan are still under analysis.

Perspectives

How does this study impact clinical practice?

  • Real-world efficacy and tolerability data for ubrogepant, rimegepant, and lasmiditan will provide important clinical evidence that will supplement results from placebo-controlled trials and inform decision­making in clinical practice.

This is a highlights summary of an oral session given at the AHSAM 2020 Virtual Annual Scientific Meeting and presented by:

Chia-Chun Chiang, MD
Headache Fellow
Mayo Clinic Arizona
Scottsdale, Arizona

The content is produced by Infomedica, the official reporting partner of ASHAM 2020 Virtual Annual Scientific Meeting. The summary text was drafted by Goldcrest Medical Writing, reviewed by Marco Vercellino, MD, an independent external expert, and approved by Jessica Ailani, MD, FAHS and Mark J. Burish, MD, PhD, the scientific editors of the program.

The presenting authors of the original session had no part in the creation of this conference highlights summary.



Headache
Clinical Studies


Scan to open on your mobile device